Envoy Medical Announces Reverse Stock Split
Envoy Medical Announces 1-For-10 Reverse Stock Split, Effective Oct. 26
Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design
Envoy Medical Surpasses 6-Month Follow-Up Visit Milestone For Pivotal Clinical Trial Evaluating Investigational Fully Implanted Acclaim Cochlear Implant; Expects To Submit Final Clinical PMA Module By End Of Q2 2027
Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant
Envoy Medical Submits Second FDA Module Of Its PMA Application For The Acclaim Cochlear Implant; Targets Final Clinical Submission In Q2 2027
Envoy Medical Announces Delaware Chancery Court Dismissal With Prejudice Of Atlas Merchant Capital Spac Fund I's Claim That It Was Not Allowed To Redeem Shares
Lake Street Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $2.5
Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio
Envoy Medical Granted Two Additional Global Patents Over Its IP Portfolio
HC Wainwright & Co. Maintains Buy on Envoy Medical, Lowers Price Target to $2
Envoy Medical Expects To Submit Four Modules, Final Module Of PMA Application Targeted For Submission In Q2 2027
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
Envoy Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $51.000K Miss $80.000K Estimate
LUCID CAPITAL MARKETS Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $2
Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.